Finvest
BLCO Eye Health · Medical devices · Pharma · Vision care · Thesis updated June 30, 2026

Dry eye growth is carrying the rebuild

01 Running thesis

Dry eye proves the leverage case

Bausch + Lomb had a strong Q1 2026. Revenue grew 9% year over year to $1.244 billion, and adjusted EBITDA rose 59%. That matters because the bull case is that the company can grow while turning more of each new sales dollar into profit.

The key driver is dry eye. MIEBO had $76 million of Q1 revenue, up 33% year over year. XIIDRA had $87 million, up 30%. Management now says this franchise has moved from launch phase to growth phase, which means selling costs should weigh less as sales scale.

The bear case starts with Surgical. Segment revenue was $228 million in Q1, up 7% as reported but only 1% in constant currency. Management blamed weather, some reimbursement pressure, a hard prior-year comparison, and a rebuild of the U.S. field force. Those may be temporary, but investors need to see better growth in Q2 and Q3.

The setup is balanced. BLCO is showing real profit leverage, and management raised 2026 adjusted EBITDA guidance to $1.01 billion to $1.06 billion. But the company has to prove XIIDRA can hold double-digit growth, Surgical can recover, and gross-to-net pressure, which means rebates and discounts taken off gross drug sales, does not eat too much of the upside.

Apr 2026Q1 2026 strengthened the thesis. Revenue rose 9%, adjusted EBITDA rose 59%, and management raised 2026 revenue and adjusted EBITDA guidance after strong MIEBO and XIIDRA growth.
Apr 2026The same Q1 update added a new watch item. Surgical grew only 1% in constant currency, so the U.S. field force rebuild now needs to show progress in the next few quarters.
Feb 2026Q4 2025 showed clear operating leverage, with 7% constant-currency revenue growth and 27% adjusted EBITDA growth. Management also raised MIEBO peak sales expectations to over $600 million.
Feb 2026The 2025 Form 10-K confirmed that enVista IOL sales returned to pre-recall levels by the fourth quarter. That removed a major Surgical overhang, though gross-to-net pressure and OBBBA reimbursement risk remained.
Oct 2025Q3 2025 improved confidence in Surgical recovery and introduced financial excellence as a clearer margin plan. MIEBO also continued to grow quickly.
Oct 2025The Q3 2025 filing showed pressure beneath the top line. Dry eye rebates rose, and Surgical profit fell despite revenue growth.
Jul 2025Q2 2025 reduced two worries. Management said U.S.-China tariffs were manageable inside guidance and gave a clearer timeline for enVista recovery by Q1 2026.
Jul 2025The Q2 2025 filing showed Pharmaceuticals margin pressure from XIIDRA gross-to-net pricing and higher MIEBO launch costs. Vision Care remained the main profit support.
02 Business model

Three ways to sell eye care

Bausch + Lomb is a full eye health company. It makes and sells about 400 products across around 100 countries. The product range runs from contact lenses and over-the-counter drops to prescription eye drugs and surgical equipment.

The model has three parts. Vision Care brings scale through contact lenses, lens care, Lumify, Blink, and PreserVision. Pharmaceuticals can grow faster when branded drugs like MIEBO and XIIDRA gain share. Surgical sells devices and consumables used in cataract and retinal procedures.

Management added a fourth operating pillar called financial excellence. In plain English, that means cost control, better sales execution, and higher margins. Q1 gave early proof, especially in Pharmaceuticals, where segment profit margin improved sharply as MIEBO and XIIDRA moved beyond their highest-spend launch period.

The model can break if drugs lose exclusivity, rebates rise faster than sales, supply issues hit key products, or Surgical sales reps do not regain momentum. The parent company, Bausch Health, also still holds a majority stake, so separation or sale timing remains part of the story.

03 Product portfolio

The portfolio that matters most

Growth engine

MIEBO and XIIDRA

These are the core dry eye prescription drugs. In Q1 2026, MIEBO revenue rose 33% year over year and XIIDRA revenue rose 30%.

Cash cow

Contact lenses and lens care

This includes Biotrue ONEday, INFUSE, ULTRA, Biotrue, and Renu. It gives Vision Care a large recurring base because people keep buying lenses and solutions.

Steady

Lumify, Blink, and PreserVision

These are consumer eye care products sold without a prescription. Q1 strength came from the consumer dry eye portfolio and Lumify, and the company began shipping PreserVision AREDS 3 and preservative-free Blink Triple Care.

Option

LUMIFY NXT

The company filed a new drug application, or NDA, for LUMIFY NXT in Q1 2026. If approved, it could extend the Lumify franchise.

Steady

enVista and premium IOLs

IOLs are artificial lenses used in cataract surgery. Premium IOLs grew 27% in Q1 2026, even while the broader Surgical segment was soft.

Option

seeLYRA surgical system

The company completed a CE Mark submission for seeLYRA in Q1 2026. A CE Mark can allow sale in Europe if regulators clear the product.

Steady

Vyzulta, Lotemax, and other prescription drugs

These drugs help round out the Pharmaceuticals segment across glaucoma, inflammation, and other eye conditions. The risk is that older products can face generic competition.

04 Business segments

Q1 mix shows Vision Care leads

Vision Care57%modest
Pharmaceuticals25%growing fast
Surgical18%flat

Segment mix uses Q1 2026 revenue: Vision Care $711 million, Pharmaceuticals $305 million, and Surgical $228 million. The total was $1.244 billion, so Vision Care is still the largest source of sales.

05 Risk factors

What could go wrong

Surgical rebuild stalls

High impact · Medium odds

Surgical grew only 1% in constant currency in Q1 2026. Management says weather, reimbursement pressure, a tough comparison, and a U.S. field force rebuild caused the shortfall. If the rebuild takes longer than planned, the segment could miss tougher comparisons later in 2026.

We watchSequential Surgical revenue growth and management comments on U.S. field force productivity in Q2 and Q3.

Dry eye growth fades too fast

High impact · Medium odds

MIEBO and XIIDRA carried the quarter, with Q1 revenue growth of 33% and 30%. That growth may slow as the year gets harder to compare against. XIIDRA is now expected to settle into low double-digit growth, so a larger slowdown would hurt the margin story.

We watchQuarterly MIEBO and XIIDRA revenue, XIIDRA market share, and management's full-year dry eye guidance.

Rebates eat the drug upside

Medium impact · Medium odds

Gross-to-net pressure means discounts, rebates, and fees reduce reported drug sales. The 2025 filings showed higher rebates from the dry eye portfolio, including XIIDRA and MIEBO. If rebates keep rising, strong demand may not fully show up in revenue or profit.

We watchGross-to-net commentary, Pharmaceuticals segment margin, and any change in payer access for MIEBO or XIIDRA.

Patent and generic pressure

High impact · Medium odds

The company faces generic competition and loss of exclusivity risk across its drug portfolio. It also has patent infringement proceedings tied to major products such as Lumify and PreserVision. A bad ruling or new generic launch could cut sales or force higher legal and marketing spend.

We watchPatent case updates, FDA generic approvals, and any loss of exclusivity dates named in filings.

Bausch Health overhang remains

Medium impact · Medium odds

Bausch Health still owns a majority stake in Bausch + Lomb. That creates uncertainty around the timing and form of a full separation, and it may also affect any potential sale of the company. Investors may apply a discount until ownership is clearer.

We watchBausch Health ownership disclosures, separation updates, and any formal sale process news.

Reimbursement and supply shocks

Medium impact · Medium odds

The One Big Beautiful Bill Act may lower reimbursements for drugs covered by government health programs. The company also faces global supply chain and geopolitical risks. The enVista IOL recall is considered resolved, but it shows how product disruptions can hit a segment quickly.

We watchGovernment reimbursement changes, product recall notices, and supply chain commentary in quarterly filings.